Carmichael D F, Stricklin G P, Stuart J M
Synergen Inc., Boulder, CO 80301.
Agents Actions. 1989 Jun;27(3-4):378-9. doi: 10.1007/BF01972827.
The type II collagen induced arthritis model was used to evaluate the efficacy of tissue inhibitor of metalloproteases (TIMP) in suppressing the disease in DBA/1 mice. Treatment began following the first clinical manifestations of the disease state. Clinical observations, histological and radiographic findings show a decreased incidence of joint erosion in the treated population relative to the controls. It is concluded that systemic administration of recombinant human TIMP suppresses the pathology of type II collagen induced arthritis.
采用II型胶原诱导性关节炎模型来评估金属蛋白酶组织抑制剂（TIMP）对DBA/1小鼠疾病的抑制效果。在疾病状态首次出现临床表现后开始治疗。临床观察、组织学和影像学检查结果显示，与对照组相比，治疗组关节侵蚀的发生率降低。结论是，重组人TIMP的全身给药可抑制II型胶原诱导性关节炎的病理过程。
